Tiffany Mao, MD
Cardiovascular Disease · Edmond, OKNPI 1891181699
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 25.5% of the total.
Across 311 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Amgen$608
- Medtronic$504
- Novartis$493
- Boehringer Ingelheim$291
- E.r. Squibb & Sons, L.L.C.$246
- plus $2K from 23 others
What the payments were for
- Travel & lodging$4007%
- Food & beverage$5,04793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 98 | $1,389 |
| Amgen | 52 | $608 |
| Medtronic(2 entities) | 6 | $504 |
| Novartis | 33 | $493 |
| Boehringer Ingelheim | 11 | $291 |
| E.r. Squibb & Sons, L.L.C. | 14 | $246 |
| AstraZeneca | 12 | $216 |
| Pfizer | 20 | $212 |
| Alnylam Pharmaceuticals Inc. | 8 | $194 |
| Novo Nordisk | 9 | $173 |
| Abbott | 6 | $133 |
| Philips North America LLC | 2 | $106 |
| Johnson & Johnson | 5 | $101 |
| Abiomed | 1 | $97 |
| Atricure, Inc. | 3 | $84 |
| Boston Scientific | 4 | $76 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $70 |
| Kestra Medical Technology Services, Inc. | 2 | $63 |
| Merck | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $56 |
| Shockwave Medical, Inc | 3 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $34 |
| Irhythm Technologies, Inc. | 2 | $28 |
| Cvrx, Inc. | 1 | $25 |
| Althera Pharmaceuticals LLC | 1 | $21 |
| Bayer | 1 | $19 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$108
How this compares
$5,447 in reported general payments places this provider in the 65th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 239 | $246,487 |
| EntrestoSacubitril/Valsartan | 90 | $115,491 |
| JardianceEmpagliflozin | 59 | $61,799 |
| Repatha SureclickEvolocumab | 76 | $59,114 |
| FarxigaDapagliflozin Propanediol | 17 | $19,886 |
| BrilintaTicagrelor | 11 | $5,247 |
| Metoprolol Succinate | 269 | $4,103 |
| Ezetimibe | 162 | $3,326 |
| Rosuvastatin Calcium | 158 | $3,250 |
| Atorvastatin Calcium | 190 | $2,130 |
| Ranolazine ErRanolazine | 18 | $1,573 |
| Olmesartan Medoxomil | 24 | $1,569 |
| Amlodipine Besylate | 154 | $1,365 |
| Midodrine Hcl | 14 | $1,070 |
| ClopidogrelClopidogrel Bisulfate | 79 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $212 | $246,487239 claims |
| NovartisEntresto | $493 | $115,49190 claims |
| Boehringer IngelheimJardiance | $291 | $61,79959 claims |
| AstraZenecaFarxiga, Brilinta | $216 | $25,13328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Edmond
- Venkatram RajaramEdmond$20K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.